Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...
A gastroenterologist has revealed a number of changes to your skin that could indicate underlying liver disease. Dr Saurabh ...
According to the NHS website, most liver diseases do not cause any symptoms in the early stages. Once you start to get ...
A doctor has shared four changes to your skin that could be a sign of liver problems. Gastroenterologist Dr Saurabh Sethi, ...
SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...
Urine pH is normally slightly acidic (5.5–6.5). Bilirubin is not normally present in urine and indicates either bile duct obstruction or intrinsic hepatic disease. Elevated levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback